| Dr Brandon Michael Bilka, MD | |
|
4076 Neely Rd, Fort Wainwright, AK 99703 | |
| (907) 361-5172 | |
| Not Available |
| Full Name | Dr Brandon Michael Bilka |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 8 Years |
| Location | 4076 Neely Rd, Fort Wainwright, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316300304 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 172966 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tanana Valley Clinic Llc | 5698056901 | 105 |
News Archive
According to new research from the U.S. eating too many eggs may increase the risk of a person developing type 2 diabetes - and this applies to both men and women.
Results of the first randomized trial testing the criteria used to diagnose heart attack are presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
› Verified 6 days ago
| Entity Name | Tanana Valley Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922559558 PECOS PAC ID: 5698056901 Enrollment ID: O20161228001991 |
News Archive
According to new research from the U.S. eating too many eggs may increase the risk of a person developing type 2 diabetes - and this applies to both men and women.
Results of the first randomized trial testing the criteria used to diagnose heart attack are presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brandon Michael Bilka, MD Walter Reed National Military Ctr, 8901 Wisconsin Avenue, Bethesda, MD 20889-0001 Ph: (301) 295-9382 | Dr Brandon Michael Bilka, MD 4076 Neely Rd, Fort Wainwright, AK 99703 Ph: (907) 361-5172 |
News Archive
According to new research from the U.S. eating too many eggs may increase the risk of a person developing type 2 diabetes - and this applies to both men and women.
Results of the first randomized trial testing the criteria used to diagnose heart attack are presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.
BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film.
Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.
› Verified 6 days ago
Dr. Kevin M. Tou, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1060 Gaffney Rd, Fort Wainwright, AK 99703 Phone: 907-361-5172 |